Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Trinity's Next Gen Launch Report Shows Pharmaceutical Launches Deliver Strong Performance in the Face of Uncertainty

      Trinity

      News provided by

      Trinity

      Oct 05, 2026, 11:15 ET

      Share this article

      Share this article


      New research finds 51% of U.S. drug launches exceeded Wall Street revenue expectations in 2025, with oncology products leading the way

      WALTHAM, Mass., Oct. 5, 2026 /PRNewswire/ -- Trinity, the leader in integrating human and artificial intelligence in life sciences commercialization, today announced the release of its 5th Annual Trinity Next Gen Launch Report, revealing that the U.S. pharmaceutical and biotechnology industry delivered its strongest launch performance since Trinity began tracking new drug launches in 2020, despite significant regulatory, economic and market uncertainty.

      The report, titled 2025 Launch Paradox: Ambiguity, Overperformance, and What Standouts from the Class of 2025 Teach Us About Launch Excellence in Uncertain Markets, analyzed 36 U.S. pharmaceutical and biotech launches in 2025. The findings show that 51% of launches exceeded Wall Street consensus revenue expectations, significantly outperforming the historical four-year average of 39%.

      The strong performance came amid a challenging environment for the life sciences industry, including drug-pricing policy uncertainty, funding pressures at the FDA and NIH, volatile capital markets, and heightened merger-and-acquisition activity. Despite these headwinds, pharmaceutical companies demonstrated an increased ability to execute successful commercial launches and accelerate patient adoption.

      "What's particularly striking about the 2025 launch class is that companies achieved the strongest commercial performance we've seen in five years during a period of extraordinary industry uncertainty," said Krista Perry, Partner, Head of Launch Excellence and Emerging Accounts, Trinity. "These companies did not wait for uncertainty to subside. They invested early, executed decisively, and created the conditions for commercial success."

      Key Findings from the 2025 Next Gen Launch Report

      Among the report's most significant findings:

      • 51% of pharmaceutical launches exceeded revenue expectations. Of the 36 U.S. launches analyzed, 51% generated at least 110% of Wall Street consensus revenue forecasts, compared with the historical four-year average of 39%. An additional 11% performed in line with expectations, while 38% underperformed.
      • Market volatility created additional challenges. U.S. biopharma M&A activity increased approximately 2.5 times, reaching $113.3 billion in 2025 compared with $46 billion in 2024, while biotechnology equity markets experienced significant fluctuations.
      • Oncology launches demonstrated exceptional performance. An impressive 90% of oncology launches exceeded Wall Street revenue forecasts, with several products generating more than 700% of first-year consensus expectations.
      • Commercial execution improved despite fewer first-in-class therapies. The number of first-in-class launches declined 39% year over year, from 34 in 2024 to 21 in 2025, suggesting that improved launch performance was driven in part by stronger commercialization strategies rather than scientific innovation alone.
      • First-time launch companies continued to close the performance gap. Among companies launching their first commercial product, 63% met or exceeded revenue expectations in 2025, continuing a two-year trend of improved performance.

      What the Most Successful Drug Launches Did Differently

      Beyond analyzing industry-wide performance, Trinity's report examines three standout pharmaceutical launches to identify the commercialization strategies that helped companies exceed expectations.

      Brinsupri® (Insmed): The first FDA-approved treatment for non-cystic fibrosis bronchiectasis generated $172.7 million in U.S. net revenue in 2025, reaching approximately 385% of Wall Street's first-year revenue forecast. The launch benefited from prior relationships with HCPs to enable successful early disease awareness initiatives, patient identification efforts and dedicated field access managers that accelerated treatment initiation.

      Tryngolza® (Ionis Pharmaceuticals): The first FDA-approved therapy for familial chylomicronemia syndrome generated $108 million in U.S. net sales in 2025, exceeding consensus forecasts by 328%. Its commercial success was supported by initiatives to improve patient diagnosis, tailored genetic testing programs, targeted and tech-enabled patient identification and comprehensive patient-support services.

      Attruby® (BridgeBio Pharma): The therapy for transthyretin amyloid cardiomyopathy generated $365.3 million in revenue in 2025, demonstrating how meaningful clinical differentiation, market expansion and reduced access barriers can help a new entrant from a first launch company compete effectively against large pharma and deliver innovation to patients.

      Across these case studies, Trinity identified three common strategies that contributed to successful commercialization: establishing meaningful clinical differentiation while investing in market expansion; building demand through early patient identification and effective field execution; and accelerating access through pricing strategies, treatment guidelines and tailored patient-support programs.

      "One of the most important lessons from this year's report is that launch excellence begins well before regulatory approval," added Perry. "The companies that significantly outperformed expectations were those that understood the patient journey, invested in identifying and educating their target populations, and made it easier for physicians and patients to access treatment. As the industry faces continued pricing pressures and increasingly competitive therapeutic markets, that level of preparation and execution will become even more critical."

      Implications for the Next Generation of Pharmaceutical Launches

      Trinity's findings suggest that the pharmaceutical industry's approach to commercialization is evolving. While clinical innovation remains essential, companies are increasingly distinguishing themselves through their ability to translate scientific advances into effective customer experience and patient access.

      The report also highlights the limitations of commercialization strategies in crowded therapeutic categories. In hereditary angioedema, for example, three products were approved in 2025, but none exceeded revenue expectations, illustrating the challenges facing new entrants when existing therapies already address substantial portions of patient need.

      Looking ahead, Trinity expects early market preparation, differentiated clinical positioning, patient identification and streamlined treatment initiation to remain central to successful pharmaceutical launches.

      The 5th Annual Trinity Next Gen Launch Report provides pharmaceutical and biotechnology executives, investors and commercialization leaders with insights into the strategies driving launch performance and the lessons that can inform future product introductions.

      To read the full report, visit: https://trinitylifesciences.com/white-papers/5th-annual-next-gen-launch-report/ 

      About Trinity

      Trinity is a life sciences commercialization company that combines deep therapeutic, functional, and commercial expertise with AI-powered platforms. For more than 30 years, pharmaceutical, biotech, and medtech companies have relied on Trinity to connect strategy, data, and execution—supporting better decisions, more confident launches, and sustained commercial performance. Trinity helps clients turn insight into action and bring innovations to market with greater speed and confidence. Learn more at www.trinitylifesciences.com.

      SOURCE Trinity

      Modal title

      Also from this source

      Trinity Acquires Verix, Adding AI-Powered Next-Best-Action and Omnichannel Orchestration to the TrinityEDGE Platform

      Trinity Acquires Verix, Adding AI-Powered Next-Best-Action and Omnichannel Orchestration to the TrinityEDGE Platform

      Trinity, the leader in integrating human and artificial intelligence for life sciences commercialization, today announced it has acquired Verix, the...

      Trinity Named to Forbes World's Best Management Consulting Firms 2026 Ranking for Third Consecutive Year

      Trinity Named to Forbes World's Best Management Consulting Firms 2026 Ranking for Third Consecutive Year

      Trinity, the leader in integrating human and artificial intelligence in life sciences commercialization, has been named to the Forbes World's Best...

      More Releases From This Source

      Explore

      Biotechnology

      Biotechnology

      Pharmaceuticals

      Pharmaceuticals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.